glp-1-directed nmda receptor antagonism for obesity treatment Emerging Role of GLP-1 Agonists the of MASH The predicted impact of GLP‐1

No significant increase in gastroparesis diagnosis was detected compared to placebo groups in any pivotal trial

Against this backdrop, researchers explored GLP1 receptor agonistsa class of medicines widely used for diabetes and obesityfor potential neuroprotective and antiinflammatory effects in the brain

These types of positive outcomes dont appear to be atypical

Liraglutide is another popular medication prescribed for weight loss

Previous analysis of trials into the efficacy of different diets, not including drugs, by the same researchers, found that while people also regained weight after stopping diets, the rate of regain was much slower, taking at least five years to get back to the weight they were before

e - h , Chow-fed Sprague-Dawley rats were dosed once-daily with s.c